OncLive » Chronic Lymphocytic Leukemia
29 FOLLOWERS
The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia.
OncLive » Chronic Lymphocytic Leukemia
1w ago
A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia ..read more
OncLive » Chronic Lymphocytic Leukemia
1w ago
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024 ..read more
OncLive » Chronic Lymphocytic Leukemia
1w ago
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting ..read more
OncLive » Chronic Lymphocytic Leukemia
1w ago
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates ..read more
OncLive » Chronic Lymphocytic Leukemia
1w ago
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies ..read more
OncLive » Chronic Lymphocytic Leukemia
1M ago
MRD-guided ibrutinib plus venetoclax displays PFS and OS benefits over fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia ..read more
OncLive » Chronic Lymphocytic Leukemia
1M ago
Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma ..read more
OncLive » Chronic Lymphocytic Leukemia
1M ago
Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax ..read more
OncLive » Chronic Lymphocytic Leukemia
1M ago
The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select patients with relapsed/refractory CLL or SLL ..read more
OncLive » Chronic Lymphocytic Leukemia
1M ago
The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications ..read more